GleamWall
中文EN

BCAB BioAtla, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1826892 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY63.6%
TTM EPS YoY177.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-277.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets4,031.1%
Debt / equity—
Current ratio0.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-105.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$1.41M$3.34M$4.58M$8.00M$9.54M$13.68M$12.36M$11.65M
SG&A expense$2.34M$2.93M$4.73M$3.26M$4.25M$4.96M$5.26M$4.59M
Operating income-$8.36M$227,000-$9.31M-$9.26M-$13.79M-$18.65M-$17.61M-$16.24M
Net income-$7.90M$452,000-$6.34M-$9.78M-$15.78M-$18.71M-$15.33M-$14.88M
EBITDA-$8.36M$227,000-$9.19M-$9.24M-$13.73M-$18.53M-$17.43M-$16.02M
EPS (basic)-4.740.27-4.22—-13.43-15.99-13.16—
EPS (diluted)-4.740.27-4.22—-13.43-15.99-13.16—
Weighted avg. shares (diluted)1.67M1.66M1.50M—1.17M1.17M1.16M—
Balance sheet
Cash & equivalents$576,000$1.54M$1.96M$7.12M$8.32M$18.21M$32.36M$49.05M
Receivables$0$2.00M—$0————
Current assets$946,000$4.26M$3.09M$8.01M$9.67M$20.61M$37.54M$51.23M
PP&E, net$0$0$0$120,000$324,000$380,000$495,000$678,000
Total assets$1.11M$9.51M$8.57M$13.83M$15.91M$27.13M$38.29M$52.42M
Current liabilities$20.69M$21.02M$20.69M$21.92M$17.98M$16.60M$16.01M$14.54M
Total liabilities$44.70M$45.74M$45.88M$50.02M$47.15M$43.87M$37.74M$38.16M
Shareholders' equity-$43.60M-$36.24M-$37.31M-$36.19M-$31.24M-$16.75M$547,000$14.27M
Shares outstanding1.67M1.66M1.66M1.27M58.79M58.72M58.40M58.10M
Cash flow statement
Operating cash flow-$967,000-$419,000-$5.27M-$7.92M-$9.88M-$14.12M-$16.29M-$16.78M
Investing cash flow——————$0$0
Financing cash flow-$1,000$2,000$110,000$6.71M-$6,000-$36,000-$395,000$9.31M
Depreciation & amortization$0$0$120,000$19,000$56,000$115,000$183,000$228,000
Stock-based compensation$538,000$619,000$956,000$1.12M$1.29M$1.38M$1.65M$1.93M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.